T6933 |
Peficitinib
|
944118-01-8
|
98.67%
|
|
Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
|
T36584 |
HNMPA-(AM)3
|
120944-03-8
|
97.22%
|
|
HNMPA-(AM)3 inhibits activation of ERK phosphorylation and stimulation of ecdysteroid production by prothyrotropin (PTTH). Furthermore, HNMPA-(AM)3 had inhibitor...
|
T14669 |
BMS-066
|
914946-88-6
|
98%
|
|
BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor. With IC50s of 9 nM and 72 nM, respectively.
|
T17184 |
Tyrosine kinase inhibitor
|
1021950-26-4
|
98%
|
|
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
|
T13233 |
Tyk2-IN-3
|
1779493-12-7
|
98%
|
|
Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).
|
T5049 |
NVP-BSK805
|
1092499-93-8
|
98%
|
|
NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.
|
T6790 |
BMS-911543
|
1271022-90-2
|
99.98%
|
|
BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.
|
T1936 |
Alectinib
|
1256580-46-7
|
99.97%
|
|
Alectinib (RG-7853) is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.
|
T3061 |
Lorlatinib
|
1454846-35-5
|
99.93%
|
|
Lorlatinib (PF-6463922) is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1...
|
T1917 |
GSK 3 Inhibitor IX
|
667463-62-9
|
99.9%
|
|
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity w...
|
T13237L |
Ropsacitinib
|
2127109-84-4
|
99.85%
|
|
Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC50: 17 nM).
|
T2485 |
Baricitinib
|
1187594-09-7
|
99.79%
|
|
Baricitinib (INCB028050) is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineopla...
|
T1835 |
Ibrutinib
|
936563-96-1
|
99.76%
|
|
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
|
T71857 |
GTP-14564
|
34823-86-4
|
99.69%
|
|
GTP-14564 is a novel tyrosine kinase inhibitor that also inhibits wt-FLT3 and ITD-FLT3. GTP-14564 inhibits the growth of interleukin-3-independent Ba/F1 expressi...
|
T12266L |
Ilginatinib maleate
|
1354799-87-3
|
99.68%
|
|
Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.
|
T2636 |
Decernotinib
|
944842-54-0
|
99.64%
|
|
Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.
|
T2487 |
Cerdulatinib
|
1198300-79-6
|
99.64%
|
|
Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.
|
T12266L2 |
Ilginatinib hydrochloride
|
1239358-85-0
|
99.55%
|
|
Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.
|
T6080 |
NVP-AEW541
|
475489-16-8
|
99.55%
|
|
NVP-AEW541 (AEW541), a potent inhibitor of IGF-1R(IC50=150 nM) and InsR(IC50=140 nM), exhibits excellent efficiency and specificity for IGF-1R in a cell-based as...
|
T6156 |
Ruxolitinib (S enantiomer)
|
941685-37-6
|
99.5%
|
|
Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.
|